Bone substitute materials delivering zoledronic acid: Physicochemical characterization, drug load, and release properties

Journal of Biomaterials Applications

Volumn 27, Issue 6, 2013, Pages 727-738

  Sörensen, Torben C ^a   Arnoldi, Jörg ^b,c   Procter, Philip ^c,d   Robioneck, Bernd ^c   Steckel, Hartwig ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^c Stryker Orthopaedics   (United States)

^d BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

bone substitute; calcium phosphate; drug delivery; physicochemical characterization; Zoledronic acid

Indexed keywords

ACTIVE AGENTS; BIOMINERALS; BISPHOSPHONATES; BONE FORMATION; BONE RESORPTION; BONE SUBSTITUTES; CARRIER SYSTEMS; CONCENTRATION-DEPENDENT; DRUG LOAD; DRUG LOADING; DRUG-DELIVERY SYSTEMS; DYNAMIC VAPOR SORPTION; IN-VITRO; IN-VIVO; ORTHOPEDIC APPLICATIONS; PHYSICO-CHEMICAL CHARACTERIZATION; PHYSICOCHEMICAL METHODS; POTENTIAL DRUG; PROLONGED RELEASE; RELEASE PROPERTY; SURFACE AREA MEASUREMENT; TRUE DENSITY; VOID FILLING; ZOLEDRONIC ACID;

ADSORPTION; BIOCERAMICS; BONE; CALCIUM PHOSPHATE; CONTROLLED DRUG DELIVERY; DRUG DELIVERY; MATERIALS; SCANNING ELECTRON MICROSCOPY; VAPORS;

CHARACTERIZATION;

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CALCIUM PHOSPHATE; DRUG CARRIER; IMIDAZOLE DERIVATIVE; ZOLEDRONIC ACID;

ADSORPTION; ARTICLE; BONE PROSTHESIS; BONE REGENERATION; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; HUMAN; MATERIALS TESTING; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY;

ADSORPTION; BONE DENSITY CONSERVATION AGENTS; BONE REGENERATION; BONE SUBSTITUTES; CALCIUM PHOSPHATES; DIPHOSPHONATES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; IMIDAZOLES; MATERIALS TESTING; MICROSCOPY, ELECTRON, SCANNING; SURFACE PROPERTIES;

EID: 84872424133     PISSN: 08853282     EISSN: 15308022     Source Type: Journal    
DOI: 10.1177/0885328211424623     Document Type: Article

References (45)

1. Frost HM. The biology of fracture healing. An overview for clinicians. Part II. Clin Orthop Relat Res. 1989 ; 248: 294-309
2. Kurashina K, Kurita H, Hirano M, Kotani A, Klein CP, de Groot K. In vivo study of calcium phosphate cements: Implantation of an alpha-tricalcium phosphate/dicalcium phosphate dibasic/tetracalcium phosphate monoxide cement paste. Biomaterials. 1997 ; 18 (7). 539-543
3. Apelt D, Theiss F, El-Warrak AO, Zlinszky K, Bettschart-Wolfisberger R, Bohner M, et al. In vivo behavior of three different injectable hydraulic calcium phosphate cements. Biomaterials. 2004 ; 25 (7-8). 1439-1451
4. Friedman CD, Costantino PD, Takagi S, Chow LC. BoneSource hydroxyapatite cement: A novel biomaterial for craniofacial skeletal tissue engineering and reconstruction. J Biomed Mater Res. 1998 ; 43 (4). 428-432
5. Larsson S, Bauer TW. Use of injectable calcium phosphate cement for fracture fixation: A review. Clin Orthop Relat Res. 2002 ; 395: 23-32
6. Ooms EM, Wolke JG, van de Heuvel MT, Jeschke B, Jansen JA. Histological evaluation of the bone response to calcium phosphate cement implanted in cortical bone. Biomaterials. 2003 ; 24 (6). 989-1000
7. Schmitz JP, Hollinger JO. The critical size defect as an experimental model for craniomandibulofacial nonunions. Clin Orthop Relat Res. 1986 ; 205: 299-308
8. Larsson S. Calcium phosphates: What is the evidence?. JOrthop Trauma. 24: S41 - S45
9. Guo D, Xu K, Han Y. The in situ synthesis of biphasic calcium phosphate scaffolds with controllable compositions, structures, and adjustable properties. J Biomed Mater Res. 2009 ; 88 (1). 43-52
10. Joschek S, Nies B, Krotz R, Goferich A. Chemical and physicochemical characterization of porous hydroxyapatite ceramics made of natural bone. Biomaterials. 2000 ; 21 (16). 1645-1658
11. Ginebra MP, Traykova T, Planell JA. Calcium phosphate cements as bone drug delivery systems: A review. JControl Release. 2006 ; 113 (2). 102-110
12. Paul W, Sharma CP. Ceramic drug delivery: Aperspective. J Biomater Appl. 2003 ; 17 (4). 253-264
13. Josse S, Faucheux C, Soueidan A, Grimandi G, Massiot D, Alonso B, et al. Novel biomaterials for bisphosphonate delivery. Biomaterials. 2005 ; 26 (14). 2073-2080
14. Arkfeld DG, Rubenstein E. Quest for the Holy Grail to cure arthritis and osteoporosis: Emphasis on bone drugdelivery systems. Adv Drug Deliv Rev. 2005 ; 57 (7). 939-944
15. Hjerten S, Levin O, Tiselius A. Protein chromatography on calcium phosphate columns. Arch Biochem Biophys. 1956 ; 65 (1). 132-155
16. Urist MR, Huo YK, Brownell AG, Hohl WM, Buyske J, Lietze A, et al. Purification of bovine bone morphogenetic protein by hydroxyapatite chromatography. Proc Natl Acad Sci. U S A. 1984 ; 81 (2). 371-375
17. Gao Y, Zou S, Liu X, Bao C, Hu J. The effect of surface immobilized bisphosphonates on the fixation of hydroxyapatite-coated titanium implants in ovariectomized rats. Biomaterials. 2009 ; 30 (9). 1790-1796
18. Fleisch H. Bisphosphonates: Mechanisms of action. Endocrine Rev. 1998 ; 19 (1). 80-100
19. Denissen H, van Beek E, Lowik C, Papapoulos S, van den Hooff A. Ceramic hydroxyapatite implants for the release of bisphosphonate. Bone Miner. 1994 ; 25 (2). 123-134
20. Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res. 2000 ; 60 (21). 6001-6007
21. Green JR. Bisphosphonates: Preclinical review. The Oncologist. 2004 ; 9: 3-13
22. Greiner S, Kadow-Romacker A, Lubberstedt M, Schmidmaier G, Wildemann B. The effect of zoledronic acid incorporated in a poly(D,L-lactide) implant coating on osteoblasts in vitro. J Biomed Mater Res. 2007 ; 80 (4). 769-775
23. Miettinen SS, Jaatinen J, Pelttari A, Lappalainen R, Monkkonen J, Venesmaa PK, et al. Effect of locally administered zoledronic acid on injury-induced intramembranous bone regeneration and osseointegration of a titanium implant in rats. J Orthop Sci. 2009 ; 14 (4). 431-436
24. Greiner S, Kadow-Romacker A, Wildemann B, Schwabe P, Schmidmaier G. Bisphosphonates incorporated in a poly(D,L-lactide) implant coating inhibit osteoclast like cells in vitro. J Biomed Mater Res. 2007 ; 83 (4). 1184-1191
25. Hnatyszyn HJ, Kossovsky N, Gelman A, Sponsler E. Drug delivery systems for the future. PDA J Pharm Sci Technol. 1994 ; 48 (5). 247-254
26. Sikavitsas VI, Temenoff JS, Mikos AG. Biomaterials and bone mechanotransduction. Biomaterials. 2001 ; 22 (19). 2581-2593
27. Frentzen M, Osborn JF, Nolden R. Use of porous hydroxyapatite in systematic periodontal treatment. A 2-year clinical study. Dtsch Zahnarztl Z. 1988 ; 43 (6). 713-718
28. Frentzen M, Osborn JF, Nolden R. Clinical example of porous hydroxyapatite ceramic in setting of systematic periodontal treatment (III). Quintessenz. 1987 ; 38 (11). 1857-1866
29. Frentzen M, Osborn JF, Nolden R. Clinical example of porous hydroxyapatite ceramic in setting of systematic periodontal treatment (II). Quintessenz. 1987 ; 38 (10). 1671-1679, 1682
30. Frentzen M, Osborn JF, Nolden R. Clinical example of porous hydroxyapatite ceramic in setting of systematic periodontal treatment (I). Quintessenz. 1987 ; 38 (9). 1509-1519
31. Misra DN, Bowen RL, Mattamal GJ. Surface area of dental enamel, bone, and hydroxyapatite: Chemisorption from solution. Calcif Tissue Res. 1978 ; 26 (2). 139-142
32. Wood NV. Jr. Specific surfaces of bone, apatite, enamel, and dentine. Science. 1947 ; 105 (2733). 531-532
33. Saalfeld U, Meenen NM, Jures TT, Saalfeld H. Solubility behaviour of synthetic hydroxyapatites in aqueous solution: Influence of amorphous constituents on pH value. Biomaterials. 1994 ; 15 (11). 905-908
34. Sharpe JR, Sammons RL, Marquis PM. Effect of pH on protein adsorption to hydroxyapatite and tricalcium phosphate ceramics. Biomaterials. 1997 ; 18 (6). 471-476
35. Aberg J, Brohede U, Mihranyan A, Stromme M, Engqvist H. Bisphosphonate incorporation in surgical implant coatings by fast loading and co-precipitation at low drug concentrations. J Mater Sci. 2009 ; 20 (10). 2053-2061
36. Peter B, Pioletti DP, Laib S, Bujoli B, Pilet P, Janvier P, et al. Calcium phosphate drug delivery system: Influence of local zoledronate release on bone implant osteointegration. Bone. 2005 ; 36 (1). 52-60
37. Aspenberg P. Bisphosphonates and implants: An overview. Acta Orthop. 2009 ; 80 (1). 119-123
38. Seo SW, Cho SK, Storer SK, Lee FY. Zoledronate reduces unwanted bone resorption in intercalary bone allografts. Int Orthop. 2009 ; 34 (4). 599-603
39. Greiner SH, Wildemann B, Back DA, Alidoust M, Schwabe P, Haas NP, et al. Local application of zoledronic acid incorporated in a poly(D,L-lactide)-coated implant accelerates fracture healing in rats. Acta Orthop. 2008 ; 79 (5). 717-725
40. Pan B, To LB, Farrugia AN, Findlay DM, Green J, Gronthos S, et al. The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone. 2004 ; 34 (1). 112-123
41. Schindeler A, Little DG. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro. Biochem Biophys Res Commun. 2005 ; 338 (2). 710-716
42. Tanzer M, Karabasz D, Krygier JJ, Cohen R, Bobyn JD. The Otto Aufranc award: Bone augmentation around and within porous implants by local bisphosphonate elution. Clin Orthop Relat Res. 2005 ; 441: 30-39
43. Bobyn JD, McKenzie K, Karabasz D, Krygier JJ, Tanzer M. Locally delivered bisphosphonate for enhancement of bone formation and implant fixation. J Bone Joint Surg. 2009 ; 91: 23-31
44. Esposito M, Hirsch JM, Lekholm U, Thomsen P. Biological factors contributing to failures of osseointegrated oral implants. (I). Success criteria and epidemiology. Eur J Oral Sci. 1998 ; 106 (1). 527-551
45. Esposito M, Hirsch JM, Lekholm U, Thomsen P. Biological factors contributing to failures of osseointegrated oral implants. (II). Etiopathogenesis. Eur J Oral Sci. 1998 ; 106 (3). 721-764